

# Journal Pre-proof

Revision and Conversion to Arthroplasty are Low Among Adolescents Undergoing Meniscal Allograft Transplantation Using the Bridge-In-Slot Technique at Midterm Follow-Up

Kyle R. Wagner, MD, Joshua T. Kaiser, MD, Ryan A. Quigley, MD, Mario Hevesi, MD PhD, Dhanur Damodar, MD, Zachary D. Meeker, BS, Eric J. Cotter, MD, Adam B. Yanke, MD PhD, Brian J. Cole, MD MBA

PII: S0749-8063(23)00662-X

DOI: <https://doi.org/10.1016/j.arthro.2023.07.059>

Reference: YJARS 58681

To appear in: *Arthroscopy: The Journal of Arthroscopic and Related Surgery*

Received Date: 21 December 2022

Revised Date: 30 July 2023

Accepted Date: 31 July 2023

Please cite this article as: Wagner KR, Kaiser JT, Quigley RA, Hevesi M, Damodar D, Meeker ZD, Cotter EJ, Yanke AB, Cole BJ, Revision and Conversion to Arthroplasty are Low Among Adolescents Undergoing Meniscal Allograft Transplantation Using the Bridge-In-Slot Technique at Midterm Follow-Up, *Arthroscopy: The Journal of Arthroscopic and Related Surgery* (2023), doi: <https://doi.org/10.1016/j.arthro.2023.07.059>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2023 Published by Elsevier on behalf of the Arthroscopy Association of North America



**Title:** Revision and Conversion to Arthroplasty are Low Among Adolescents Undergoing Meniscal Allograft Transplantation Using the Bridge-In-Slot Technique at Midterm Follow-Up

**Running Title:** Meniscal Allograft Transplants in Adolescents

**Authors:** Kyle R. Wagner<sup>1</sup> MD, Joshua T. Kaiser<sup>1</sup> MD, Ryan A. Quigley<sup>1</sup> MD, Mario Hevesi<sup>1</sup> MD PhD, Dhanur Damodar<sup>1</sup> MD, Zachary D. Meeker<sup>1</sup> BS, Eric J. Cotter<sup>1</sup> MD, Adam B. Yanke<sup>1</sup> MD PhD, Brian J. Cole<sup>1</sup> MD MBA

<sup>1</sup>Midwest Orthopaedics at Rush University Medical Center, Chicago, IL, USA

Approved by Rush Institutional Review Board – ORA# 22050101-IRB01

**Corresponding Author:**

Brian J. Cole MD MBA

Associate Chairman and Professor, Department of Orthopedics

Chairman, Department of Surgery, Rush OPH

Section Head, Cartilage Restoration Center at Rush

Rush University Medical Center

1611 W Harrison, Suite 300

Chicago, IL 60612

312-432-2381

Brian.cole@rushortho.com

**Email Addresses:**

Joshua T. Kaiser: [joshkaiser28@gmail.com](mailto:joshkaiser28@gmail.com)

Kyle R. Wagner: [kylewagner85@gmail.com](mailto:kylewagner85@gmail.com)

Ryan A. Quigley: [rq0007@mix.wvu.edu](mailto:rq0007@mix.wvu.edu)

Mario Hevesi: [hevesimario@gmail.com](mailto:hevesimario@gmail.com)

Dhanur Damodar: [dhanurdamodar@gmail.com](mailto:dhanurdamodar@gmail.com)

Zachary D. Meeker: [zmeeker8@gmail.com](mailto:zmeeker8@gmail.com)

Eric J. Cotter: [eric.cotter21@gmail.com](mailto:eric.cotter21@gmail.com)

Adam B. Yanke: [adam.yanke@rushortho.com](mailto:adam.yanke@rushortho.com)

**Social Media Handles:**

Kyle R. Wagner: [kylewagner85@gmail.com](mailto:kylewagner85@gmail.com)

**Twitter:** @KyleWagsMD

**Instagram:** kylewagsss

Joshua T. Kaiser: [joshkaiser28@gmail.com](mailto:joshkaiser28@gmail.com)

**Instagram:** joshkaiser28

Ryan A. Quigley: [rq0007@mix.wvu.edu](mailto:rq0007@mix.wvu.edu)

Mario Hevesi: [hevesimario@gmail.com](mailto:hevesimario@gmail.com)

**Twitter:** @MarioHevesiMD

**Instagram:** mariohevesimd

Dhanur Damodar: [dhanurdamodar@gmail.com](mailto:dhanurdamodar@gmail.com)

Zachary D. Meeker: [zmeeker8@gmail.com](mailto:zmeeker8@gmail.com)

Eric J. Cotter: [eric.cotter21@gmail.com](mailto:eric.cotter21@gmail.com)

Adam B. Yanke: [adam.yanke@rushortho.com](mailto:adam.yanke@rushortho.com)

**Twitter: @AdamYankeMD**

**Instagram: adamyankemd**

Brian J. Cole

**Twitter: @BrianColeMD**

**Instagram: brianjcolemd**

Journal Pre-proof

1 **Title:** Revision and Conversion to Arthroplasty are Low Among Adolescents Undergoing  
2 Meniscal Allograft Transplantation Using the Bridge-In-Slot Technique at Midterm Follow-Up

3 **Abstract:**

4 Purpose: To report midterm outcomes following primary medial and lateral meniscal allograft  
5 transplantation (MAT) with fresh-frozen allografts implanted with the bridge-in-slot technique in  
6 the adolescent patient population.

7 Methods: Adolescent patients less than 18 years old at the time of primary MAT from 1999-2016  
8 were retrospectively identified. International Knee Documentation Committee (IKDC) subjective  
9 form, Lysholm, and Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales scores were  
10 collected preoperatively and at 1-year, 2-years, and a minimum of 5-years follow-up. Thresholds  
11 for achieving clinically significant outcomes were calculated and the proportion of patients  
12 achieving minimal clinically important difference (MCID), patient acceptable symptomatic state  
13 (PASS), and substantial clinical benefit (SCB) was determined. Meniscus reoperation (partial,  
14 subtotal, or total meniscectomy, repair, or failure) and failure (revision MAT or conversion to  
15 arthroplasty) rates were determined.

16 Results: Forty-four (female n=33; male n=11) of 62 identified patients met inclusion criteria and  
17 were followed for a mean of  $9.5 \pm 3.8$  years (range: 5.0-17.7). Lateral MAT was performed in most  
18 patients (n=35/44; 80%). Isolated MAT was performed in 27 (61%) patients. Common  
19 concomitant procedures included osteochondral allograft transplantation (OCA) (32%),  
20 autologous chondrocyte implantation (ACI) (18%), and anterior cruciate ligament reconstruction  
21 (ACLR) (14%). MCID, PASS, and SCB were achieved by patients at a minimum 5-year follow-  
22 up for IKDC (62%;76%;31%), Lysholm (62%;79%;23%), and KOOS questionnaires (Pain

23 [65%;81%;41%], Symptoms [58%;81%;47%], Activities of Daily Living [53%;77%;35%], Sport  
24 [86%;75%;50%], and Quality of Life [59%;81%;59%]), respectively. Eleven patients (25%)  
25 underwent reoperation at an average of  $5.9 \pm 4.5$  years (range: 0.8 – 14.0) following MAT. Three  
26 (7%) patients met criteria for failure, requiring revision MAT an average of  $3.8 \pm 1.1$  years (range:  
27 2.8-4.9) post-transplant. No patients underwent arthroplasty. Overall survival free from failure at  
28 1, 2, 5, and 10 years was 100%, 100%, 93%, and 93%, respectively. At the time of final follow-  
29 up, 80% of patients reported satisfaction with their current physical status.

30 Conclusion: Primary MAT in adolescent patients resulted in significant and durable functional  
31 improvements at mid- to long-term follow-up. At an average of 9.5 years postoperatively,  
32 meniscal reoperation rate was 25% while graft survival free of revision MAT was 93%.  
33 Adolescents undergoing MAT demonstrated similar functional outcomes and graft survivability  
34 when compared to available adult MAT literature.

35 Level of Evidence: Level IV, Retrospective Case Series

**36 Introduction:**

37 Youth meniscus injuries are increasingly common and may be attributable to increases in  
38 organized athletic competition, sport specialization, and injury awareness.<sup>1-5</sup> Meniscus injuries can  
39 occur in isolation or in conjunction with other injuries such as anterior cruciate ligament (ACL)  
40 tears, focal chondral injuries, and tibial fractures.<sup>1,5</sup> Discoid menisci have also been identified as  
41 risk factors for meniscus injury.<sup>6,7</sup>

42 Current treatment guidelines for meniscus injuries recommend that meniscal tissue be  
43 preserved whenever feasible, as subtotal or total meniscectomy has been shown to increase contact  
44 forces and negatively impact long-term joint health.<sup>8,9</sup> Meniscus preservation is especially relevant  
45 in adolescents because this population will place greater demand on the knee joint over a longer  
46 period of time than older adults.<sup>4,10</sup> Although the meniscus is thought of as a relatively avascular  
47 structure, meniscus tissue is richly vascular at birth and maintains some degree of vascularity to  
48 allow for growth prior to regressing into the periphery by adulthood.<sup>11,12</sup> Therefore, adolescent  
49 menisci are generally thought to be more amenable to surgical repair given better blood flow and  
50 healing potential.<sup>13,14</sup> Longitudinal vertical and bucket-handle tears are fairly common meniscal  
51 injury patterns and can routinely be managed with arthroscopic repair. However, radial, oblique,  
52 horizontal, and complex tears are historically thought to fare poorly following repair and often go  
53 on to partial meniscectomy.<sup>1,14,15</sup>

54 Even following conservative partial meniscectomy, outcomes in youth populations are  
55 suboptimal. Long-term outcome studies have found that up to 80% of children and adolescents  
56 have evidence of degenerative changes as early as five years post-meniscectomy, while 75% and  
57 60% report persistent pain and dissatisfaction with clinical outcomes, respectively.<sup>9,16</sup> Previously,  
58 there was hesitation to indicate MAT in children and adolescents due to concerns about allograft

59 longevity and the unknown effects of transplantation on skeletal development.<sup>4,17</sup> Initial short-term  
60 outcome reports have demonstrated consistent improvement in pain, function, and activity levels,  
61 suggesting that MAT is a viable treatment option for children and adolescents.<sup>6,10,18</sup> However, the  
62 majority of available outcomes are limited by short-term follow-up. Studies with increased follow-  
63 up are needed in this patient population to evaluate for durability of clinical benefit as well as  
64 allograft survivorship.

65         The purpose of this investigation was to report midterm outcomes following primary  
66 medial and lateral meniscal allograft transplantation (MAT) with fresh-frozen allografts implanted  
67 with the bridge-in-slot technique in the adolescent patient population. The authors hypothesized  
68 that at a minimum five-year follow-up, MAT in the adolescent population would demonstrate  
69 significant improvements in patient-reported outcomes as well as allograft survivorship similar to  
70 reported rates of previous studies for adult populations.

## 72 **Methods:**

### 73 Patient Population:

74         Local Institutional Review Board approval was obtained prior to study initiation. A  
75 prospectively collected database from a single institution was retrospectively reviewed for patients  
76 who underwent primary MAT with a single surgeon between 1999-2016. Patients who underwent  
77 any concomitant procedures at the time of MAT were included. Inclusion criteria included the  
78 following: (1) primary MAT for symptomatic meniscal deficiency for which conservative  
79 treatment had failed, (2) age 18 years or younger at the time of primary surgery, and (3) minimum  
80 5-year follow-up. Patient-reported outcomes and an updated surgical history were collected to



81 calculate reoperation and failure rates. Subsequent meniscal reoperation was defined as partial,  
82 subtotal, or total meniscectomy, or meniscal repair. MAT failure was defined as revision MAT or  
83 conversion to unicompartmental or total knee arthroplasty.<sup>19</sup>

#### 84 Surgical Technique:

85 All MATs were performed by the senior author, a fellowship-trained orthopedic surgeon  
86 who operates a high-volume joint preservation clinical practice. For both medial and lateral MAT,  
87 the senior author utilized fresh-frozen, non-irradiated meniscal grafts fixated in bone troughs using  
88 the bridge-in-slot technique.<sup>20-22</sup> As previously described, the Pollard method was used for  
89 allograft matching.<sup>23</sup> If present, the senior author will also treat associated pathology or  
90 abnormalities at the time of MAT, such as lower extremity malalignment, focal chondral defects,  
91 or ligamentous instability. Realignment osteotomy was typically performed concomitantly with  
92 MAT if patients had  $\geq 5$  degrees of mechanical axis malalignment on coronal radiographs. At the  
93 time of transplantation, the meniscus is then debrided to a bleeding peripheral rim of 1- to 2-mm.  
94 The anterior and posterior horns are subsequently resected. To prepare the meniscal slot  
95 (approximately 8 mm wide and 10 mm deep), an initial slot guide is first made using a 4.5-mm  
96 burr. In the presence of an open physis, intraoperative imaging can confirm the protection of the  
97 physis in relation to the bone trough. A guide pin is then placed using an over-the-top style slot  
98 guide. A 7-mm reamer is used to over-ream the guide pin and the slot is refined using a box cutter,  
99 dilating rasp, and a bone-cutting shaver utilizing a dovetail technique. When possible, the back  
100 wall of the tibia is preserved to help prevent posterior displacement, but at times it may be  
101 necessary to remove in order to improve the overall seating of the allograft. While the tibial slot is  
102 being prepared, the allograft is thawed in normal saline on the sterile back surgical table.

103           The meniscal allograft bone bridge is created using reciprocating saw between the anterior  
104 and posterior horn of the donor allograft. A 0-polydioxanone (PDS) suture is then placed through  
105 the posterior third of the meniscus to assist with allograft insertion into the joint and positioning  
106 within the tibial slot. We do not generally employ transosseous sutures within the slot. With the  
107 knee in flexion, a knotless suture anchor (SwiveLock, Arthrex, Inc., Naples, FL) is placed  
108 anteriorly on the far side of the meniscal allograft to secure the allograft bone bridge to the recipient  
109 tibial tunnel. For circumferential fixation, approximately 8 to 10 vertical mattress sutures are  
110 placed using an inside-out technique (FiberWire, Arthrex, Inc., Naples, FL). In one case where  
111 medial MAT and concomitant ACL reconstruction was performed, a modified bone block  
112 technique was used. In this patient, the bone block was split and the posterior block was shuttled  
113 into the joint after femoral fixation of the ACL graft. The posterior block was then fixated with  
114 transosseous sutures, inside out repair performed, and finally transosseous sutures were used to  
115 fixate the anterior horn. After confirming satisfactory meniscus placement and stability, incisions  
116 are closed in standard fashion.

117

#### 118 Rehabilitation Protocol:

119           Between postoperative weeks 0-2, patients begin heel touch weight bearing with crutches  
120 hinged knee brace locked in full extension for all activities. Exercise during this time period is  
121 limited to heel slides, quad sets, patellar mobs, and straight leg raises. Knee flexion is also limited  
122 from 0 to 90 degrees when non-weight bearing. During weeks 2-8 postoperatively, patients  
123 maintain heel touch weight bearing with crutches, with progression to full weight bearing by 6-8  
124 weeks. When non-weight bearing during this timeframe, the knee immobilizer should continue to  
125 be worn and locked at 0-90 degrees but can be removed for sleep. Bracing can be discontinued at

126 8 weeks. Additionally, patients should continue range of motion exercises as tolerated between  
127 weeks 2-8, with no restriction thereafter. Closed chain exercises are slowly introduced, with  
128 gradual return to functioning activities at 12 to 20 weeks. Patients are allowed to return to full  
129 activity by 5 months post-operatively once cleared by the attending physician.

130

#### 131 Data Collection:

132 International Knee Documentation Committee (IKDC) subjective form, and Knee injury  
133 and Osteoarthritis Outcome Score (KOOS subscales: Pain, Symptoms (SXS), Activities of Daily  
134 Living (ADL), Sport, and Quality of Life (QOL), and Lysholm scores were collected  
135 preoperatively and at 1-year, 2-year, and at a minimum 5-year follow up. All procedures prior to  
136 index surgery related to the operative knee, concomitant procedures, as well as the incidence of  
137 reoperations and failures were recorded. Postoperative satisfaction was assessed with a “yes” or  
138 “no” answer to the question, “Considering all the activities you have during your daily life, your  
139 level of pain, and your functional impairment, do you consider that your current state is  
140 satisfactory?”

141

#### 142 Statistical Analysis

143 Descriptive statistics for binomial variables were reported as frequencies (proportions) and  
144 continuous variables were reported as means with standard deviations. Mann Whitney U,  
145 Wilcoxon signed rank, paired or unpaired t-tests were utilized when comparing preoperative and  
146 postoperative patient-reported outcome measures. Shapiro-Wilk testing determined normality of  
147 the data. Fisher’s Exact test was used if frequencies for variables were less than 5 and Chi-square

148 analysis was used for comparing categorical variables. Thresholds for achieving clinically  
149 significant outcomes (CSOs) were established using a distribution method for minimal clinically  
150 important difference (MCID).<sup>24</sup> Patient acceptable symptomatic state (PASS) and substantial  
151 clinical benefit (SCB) were derived using an anchor-based method.<sup>24</sup> A receiver operating  
152 characteristic (ROC) curve with an area under the curve (AUC) of less than 0.7 and 0.8 was  
153 considered an acceptable and excellent predictor, respectively. Kaplan-Meier survival analysis was  
154 utilized to determine survival probabilities. Cox proportional hazards modelling was utilized to  
155 evaluate associations between preoperative and intraoperative variables with failure. P-values less  
156 than 0.05 were considered statistically significant. Statistical analyses were performed using  
157 RStudio Version 4.1.1 (RStudio, Boston, MA).

158

## 159 **Results**

### 160 Demographics

161 Sixty-two patients met study inclusion criteria during initial database review. Forty-four of  
162 the 62 identified patients (71%) agreed to participate in the study and were consented prior to data  
163 analysis. The remaining 18 patients who underwent MAT during the timeframe were unable to be  
164 reached for follow-up (n=16) or refused study participation (n=2). The mean age of included  
165 patients was  $16.1 \pm 1.9$  years and 33 patients were female (75%) (Table 1). The mean BMI was  
166  $23.4 \pm 3.4$  kg/m<sup>2</sup> and patients were followed for a mean of  $9.5 \pm 3.8$  years (range: 5.0-17.7). Medial  
167 meniscus transplantation was performed in 9 patients (20%) and lateral meniscus transplantation  
168 was performed in 35 patients (80%). Eleven patients (25%) were diagnosed with a discoid lateral  
169 meniscal tear and were referred to the senior author for management for symptoms refractory to

170 meniscectomy. All included patients had undergone a prior meniscectomy at a mean time  $1.2 \pm$   
171 0.9 years (range: 0.1 – 3.9) prior to MAT. Nine (20%) and two (4.5%) patients were previously  
172 treated with anterior cruciate ligament reconstruction (ACLR) or osteochondritis dissecans  
173 fixation prior to primary MAT, respectively. In 27 (61%) patients, a concomitant procedure was  
174 performed, the most common being osteochondral allograft transplantation (OCA) ( $n = 14/44$ ,  
175 32% [lateral femoral condyle (LFC),  $N = 13$ ; medial femoral condyle (MFC),  $N = 1$ ), autologous  
176 chondrocyte implantation (ACI) ( $n = 8/44$ , 18% [MFC,  $N = 1$ ; LFC,  $N = 6$ ; patellar and LFC,  $N =$   
177 1]) and ACLR ( $n = 6/44$ , 14%) (Table 1).

178

### 179 Patient-Reported Outcomes

180 Significant improvements in all patient-reported outcome measures for each postoperative  
181 timepoint analyzed (1-year, 2-year, and most-recent follow-up) were appreciated when compared  
182 to preoperative scores ( $p < .05$ , Figure 1, Supplemental Table 1). Of note, while Lysholm scores at  
183 final follow-up were significantly improved when compared to baseline ( $p = .018$ ), a significant  
184 decrease was observed in Lysholm scores when comparing final follow-up outcome scores to  
185 scores at 2 years postoperatively ( $p = .048$ ). This was an isolated finding as no other PROM  
186 demonstrated a significant decline in scores between the short-term and most recent follow-up  
187 timepoints.

188

### 189 Clinically Significant Outcomes

190 Three patients met criteria for failure prior to 5-year follow-up and were excluded from CSO  
191 analysis. Thresholds for achieving CSOs were calculated with all PROMs achieving an area under

192 the curve (AUC)  $\geq .700$  for PASS (Supplemental Table 1). Conversely, only the Lysholm form  
193 had an acceptable AUC for SCB (AUC = .750). The proportions of patients achieving CSOs were  
194 calculated (Table 3). A majority of patients achieved MCID and PASS for each PROM analyzed.  
195 SCB for the subjective IKDC form was achieved by a minority of patients (N = 5/16, 31%). At the  
196 time of final follow-up, however, 80% of patients stated they were satisfied with their overall  
197 postoperative condition.

198

199

#### 200 Reoperations and failures

201 Fourteen patients (32%) underwent a reoperation on the ipsilateral knee at an average 5.0  
202  $\pm$  4.3 years (range: 0.8 – 14.0) following MAT. Eleven patients underwent a reoperation and did  
203 not subsequently meet criteria for failure (Table 1). The most common reoperation was partial  
204 meniscectomy (n=9), followed by subtotal (n=2) and total meniscectomy (n=2), and meniscal  
205 repair (n=1). Two patients who had a subsequent total meniscectomy underwent RMAT at a mean  
206 2.68 years following meniscectomy. The remaining two patients who received a subtotal  
207 meniscectomy have not undergone subsequent surgeries at a mean 6.2 years of follow-up. An  
208 additional three patients underwent non-meniscal reoperations including synovectomy and lysis of  
209 adhesions (n=1), articular cartilage debridement (n=1), and OCA (n=1) at a mean 1.3 years  
210 following MAT.

211

212 Female patients were significantly more likely to undergo a meniscal reoperation (p =  
213 0.039). Kaplan-Meier estimations were performed to assess probability of requiring a reoperation.

214 Overall probability of being reoperation-free at 1, 2, 5, and 10 years was 96%, 91%, 80%, 71%,  
215 respectively (Figure 2A). Three (7%) patients met criteria for failure at an average of  $3.8 \pm 1.1$   
216 years (range: 2.8-4.9) post-transplant. All three patients were treated with revision MAT. No  
217 patients were converted to arthroplasty or received subsequent realignment osteotomy. MAT  
218 survival free from failure at 1, 2, 5, and 10 years was 100%, 100%, 93%, 93%, respectively (Figure  
219 2B). Log-rank testing found no difference in survival free from failure based on sex ( $p = .710$ ),  
220 meniscus laterality ( $p = .485$ ), or concomitant surgery of any kind ( $p = .234$ ), including corrective  
221 alignment procedures ( $p = .696$ ), ACLR ( $p = .525$ ), or cartilage procedures ( $p = .718$ ). Log-rank  
222 testing also found no difference in reoperation rates based on sex ( $p = .110$ ), meniscus laterality ( $p$   
223  $= .910$ ), or concomitant surgery of any kind ( $p = .118$ ), including corrective alignment procedures  
224 ( $p = .324$ ), ACLR ( $p = .483$ ), or cartilage procedures ( $p = .765$ ). Reoperations and failure data  
225 stratified by meniscal laterality is present in Supplemental Table 2.

226

## 227 Discussion

228 The primary findings of this study were Lysholm, IKDC subjective form, and all KOOS  
229 subscale outcome measures were significantly improved in the short-term postoperative period  
230 and were sustained at final, midterm follow-up. Additionally, a majority of patients achieved  
231 MCID and PASS for all questionnaires examined at midterm follow-up. The survivorship free  
232 from reoperation and failure at 5 years post-operatively was 71% and 93%, respectively. The  
233 results demonstrate that MAT is a safe, effective treatment option for indicated patients in this  
234 select population even when performed at the time of other major concomitant procedures. This  
235 study is of important clinical relevance given the overall lack of substantial literature documenting  
236 MAT outcomes in the adolescent patients at midterm follow-up.

237 Previous data regarding meniscal allograft transplantation is largely based on outcomes in  
238 adult populations.<sup>25,26</sup> Recent meta-analyses of adult MAT outcomes literature indicates MAT  
239 survivability ranges between 85.8% and 89.2% depending on compartment laterality at five-years  
240 and 74% at 10-years postoperatively.<sup>25,26</sup> Despite the bevy of literature on MAT outcomes in  
241 adults, only a handful of case series studying MAT within adolescent populations exist, and those  
242 available are limited by short-term follow-up. Nevertheless, reported outcomes demonstrate a level  
243 of functional success and survivability consistent with the findings in adult populations and the  
244 results of this case-series.

245 A previous clinical report of adolescent patients who underwent MAT performed by the  
246 senior author was conducted in 2016. This study included 32 patients (mean age 15.4 years) at a  
247 minimum 2-year follow-up.<sup>6</sup> Similar to the present study, a significant proportion of patients (48%)  
248 underwent a concomitant procedure at the time of MAT. Substantially fewer patients underwent  
249 meniscal reoperation (6%) or any reoperation (22%) when compared to the present study (32%  
250 and 39%, respectively). Additionally, no revision MATs were performed in the 2016 paper by  
251 Riboh et al., while three were performed at a mean 3.8 years following primary MAT in the present  
252 study.

253 More recently in 2021, Smith et al. completed a review of a public database of 49 children's  
254 hospitals to evaluate the epidemiology of MAT procedures in patients 25 years old or younger.<sup>4</sup>  
255 The final cohort included 67 patients with a mean age of 16.6 years, though final follow-up  
256 timeframes were not reported. The most common concomitant procedures performed at time of  
257 MAT were ACLR (n = 11; 16.4%) and either osteochondral graft or ACI (n = 6; 9%). The authors  
258 reported a reoperation rate of 18% (n = 12) among the included patients, with reoperations  
259 occurring a median of 224 days (range: 47-949 days) after transplantation. However, because the



260 data was sourced from a public registry, direct patient follow-up could not be obtained, which  
261 prevented analysis of both clinical outcomes and additional treatment that may have occurred at a  
262 facility outside of the database.

263 In a study of 23 patients undergoing MAT at a median age of 17, Middleton et al. reported  
264 that all patient-reported outcomes measured had significantly improved at most-recent follow-up  
265 (mean, 3.8 years) when compared to preoperative baseline. None of the 23 patients in the cohort  
266 met criteria for failure, defined as graft removal or meniscectomy resulting in functional  
267 deficiency.<sup>10</sup> Additionally, Kimura et al. reported successful outcomes in a small cohort of 6  
268 pediatric patients at a mean follow-up of 5.2 years using meniscal allografts donated from adult  
269 patients undergoing total knee arthroplasty. No failures were reported in this cohort, defined more  
270 conservatively as graft removal, complications, or subsequent surgery.<sup>27</sup> With failure definitions  
271 varying widely between studies, it is hard to compare failure rates. The present study reported a  
272 7% failure rate due to revision MAT which is comparable to adult studies at similar time points.<sup>22</sup>

273 Chondral concomitant procedures were performed with notable frequency in the present  
274 study as well as in the studies published by both Riboh et al.<sup>6</sup> and Smith et al.<sup>4</sup> It is worth noting  
275 that previous studies have demonstrated that concomitant chondral procedures did not affect  
276 outcomes in MAT.<sup>23</sup> Similar results were redemonstrated in the present investigation as log-rank  
277 testing found no difference in survivability or reoperation based on concomitant surgery of any  
278 kind (Figure 2). The variable closest to significance for association with reoperations was sex ( $p =$   
279  $.110$ ). There was a significantly greater frequency of female patients who underwent reoperation  
280 and did not subsequently fail ( $p = .039$ ). At a minimum 2-year follow-up, Frank et al., using the  
281 same database as the present study, found no increase in reoperations between male and female  
282 patients under 40 years ( $p = .902$ ). Female patients were, however, more likely to undergo

283 subsequent revision MAT ( $p = .003$ ). The association between sex on reoperation rates has not  
284 been seen in other, large database studies.<sup>28,29</sup>

285         Additionally, a majority of cases in the present study were of lateral MAT (80%). In a 2018  
286 meta-analysis of midterm and long-term studies, Bin et al. found no differences in failure between  
287 lateral and medial MAT.<sup>25</sup> However, superior Lysholm and pain scores were observed for lateral  
288 MAT. The study was limited, however, by a small sample size as only three studies reported  
289 PROMs (42 medial and 51 lateral MATs). Further, various allograft fixation and processing  
290 techniques were included. More recent studies with fresh-frozen allografts using bone fixation  
291 have not appreciated similar differences in PROMs.<sup>30,31</sup> Lastly, the present study used the bone  
292 bridge using the trough or bridge-in-slot technique, which is one option among many others (such  
293 as soft tissue fixation, bone plugs, keyhole bone bridge).<sup>32,33</sup> Optimal fixation techniques remain  
294 debated as comparisons are difficult due to frequency of concomitant procedures, different patient  
295 populations, and surgeon experience.

296         The present study reported that 11 patients (25%) were diagnosed with a discoid lateral  
297 meniscal tear as the primary indication for MAT. These tears have been shown to increase the risk  
298 of early onset osteoarthritis and subsequent total knee arthroplasty (TKA).<sup>7</sup> In 2016, Ramme et al.  
299 demonstrated that in young women aged between 25-30 with torn discoid lateral menisci, MAT  
300 reduced pain, improved function, and was more effective at delaying TKA when compared to  
301 partial meniscectomy. Partial meniscectomy required TKA at an average of 12.5 years, compared  
302 to 17.3 years in the subset of patients that underwent MAT. However, MAT was more resource  
303 intensive, requiring \$14,470 of care-related expenditure compared to \$10,430 in partial  
304 meniscectomy patients.<sup>34</sup> The findings of Ramme et al., in conjunction with the outcomes of the

305 present study, suggests that MAT can serve as a viable treatment modality in the management of  
306 discoid lateral meniscal tears.

307         Lastly, patients undergoing MAT may return to competitive and recreational sports, as  
308 tolerated and as has been previously reported by our group.<sup>35,36</sup> Although the present study did not  
309 examine return-to-sport data, it is crucial to have comprehensive discussions about these data to  
310 establish expectations with adolescent patients. In the senior author's practice, patients are  
311 informed about the high risk of re-tear if they return to pivoting sports, which may necessitate  
312 subsequent surgeries. Ultimately, thorough preoperative discussions that focus on patient-specific  
313 goals help patients assess the risk associated with a traumatic meniscal re-tear and the need to limit  
314 their involvement in sports.

315         Overall, this study illustrates that midterm outcomes of MAT in this cohort of adolescent  
316 patients significantly increases in functional outcomes, with low probability of graft failure.  
317 However, further research of MAT outcomes in this demographic remains warranted. A primary  
318 area of future study should evaluate the chondroprotective effects of MAT in adolescents through  
319 imaging studies, especially in light of inconclusive results in studies of adult populations.<sup>37</sup> Long-  
320 term reporting of MAT outcomes remains necessary to better elucidate overall treatment prognosis  
321 and consequences of the procedure.

322

### 323 **Limitations**

324         This study is not without limitations. Performance bias may be evident as the cohort of  
325 patients in this study were treated by a single surgeon who operates a high-volume MAT practice.  
326 Therefore, the outcomes in this cohort may not be generalizable for adolescent patients undergoing

327 primary MAT at other institutions. Given the overall follow-up rate of 71%, a possible transfer  
328 bias is present, as the eighteen patients who were not included may differ in outcomes from patients  
329 in the present study, thus potentially confounding the results. Additionally, 61% of patients in this  
330 cohort experienced concomitant procedures, which may impact functional outcomes, reoperation  
331 rates, and graft survivability compared to patients who are treated with isolated MAT. The present  
332 study was also confined to a retrospective analysis of functional scores and re-operations.  
333 Advanced imaging of each patient at final follow up to evaluate chondral or meniscal status of the  
334 knee was not routinely obtained. Therefore, conclusions regarding about physal safety following  
335 MAT are limited.<sup>6</sup>

336

### 337 **Conclusion**

338 Primary MAT in adolescent patients resulted in significant and durable functional improvements  
339 at mid- to long-term follow-up. At an average of 9.5 years postoperatively, meniscal reoperation  
340 rate was 25% while graft survival free of revision MAT was 93%. Adolescents undergoing  
341 MAT demonstrated similar functional outcomes and graft survivability when compared to  
342 available adult MAT literature.

343 **References**

- 344 1. Shieh A, Bastrom T, Roocroft J, Edmonds EW, Pennock AT. Meniscus Tear Patterns in  
345 Relation to Skeletal Immaturity: Children Versus Adolescents. *Am J Sports Med.*  
346 2013;41(12):2779-2783. doi:10.1177/0363546513504286
- 347 2. Bellisari G, Samora W, Klingele K. Meniscus tears in children. *Sports Med Arthrosc Rev.*  
348 2011;19(1):50-55. doi:10.1097/JSA.0b013e318204d01a
- 349 3. Purvis JM, Burke RG. Recreational injuries in children: incidence and prevention. *J Am*  
350 *Acad Orthop Surg.* 2001;9(6):365-374. doi:10.5435/00124635-200111000-00002
- 351 4. Smith HE, Lyons MM, Patel NM. Epidemiology of Meniscal Allograft Transplantation at  
352 Children's Hospitals in the United States. *Orthop J Sports Med.* 2021;9(9):1-5.  
353 doi:10.1177/23259671211034877
- 354 5. Stanitski CL, Harvell JC, Fu F. Observations on acute knee hemarthrosis in children and  
355 adolescents. *J Pediatr Orthop.* 1993;13(4):506-510. doi:10.1097/01241398-199307000-  
356 00016
- 357 6. Riboh JC, Tilton AK, Cvetanovich GL, Campbell KA, Cole BJ. Meniscal Allograft  
358 Transplantation in the Adolescent Population. *Arthroscopy.* 2016;32(6):1133-1140.e1.  
359 doi:10.1016/j.arthro.2015.11.041
- 360 7. Kocher MS, Logan CA, Kramer DE. Discoid Lateral Meniscus in Children: Diagnosis,  
361 Management, and Outcomes. *J Am Acad Orthop Surg.* 2017;25(11):736-743.  
362 doi:10.5435/JAAOS-D-15-00491
- 363 8. Rao AJ, Erickson BJ, Cvetanovich GL, Yanke AB, Bach BR, Cole BJ. The Meniscus-  
364 Deficient Knee: Biomechanics, Evaluation, and Treatment Options. *Orthop J Sports Med.*  
365 2015;3(10):1-13. doi:10.1177/2325967115611386
- 366 9. Manzione M, Pizzutillo PD, Peoples AB, Schweizer PA. Meniscectomy in children: a long-  
367 term follow-up study. *Am J Sports Med.* 1983;11(3):111-115.  
368 doi:10.1177/036354658301100301
- 369 10. Middleton S, Asplin L, Stevenson C, Thompson P, Spalding T. Meniscal allograft  
370 transplantation in the paediatric population: early referral is justified. *Knee Surg Sports*  
371 *Traumatol Arthrosc.* 2019;27(6):1908-1913. doi:10.1007/s00167-019-05437-y
- 372 11. Fox AJS, Wanivenhaus F, Burge AJ, Warren RF, Rodeo SA. The human meniscus: A review  
373 of anatomy, function, injury, and advances in treatment. *Clinical Anatomy.* 2015;28(2):269-  
374 287. doi:10.1002/ca.22456
- 375 12. Bryceland JK, Powell AJ, Nunn T. Knee Menisci. *Cartilage.* 2017;8(2):99-104.  
376 doi:10.1177/1947603516654945

- 377 13. Liechti DJ, Constantinescu DS, Ridley TJ, Chahla J, Mitchell JJ, Vap AR. Meniscal Repair  
378 in Pediatric Populations: A Systematic Review of Outcomes. *Orthop J Sports Med.*  
379 2019;7(5):2325967119843355. doi:10.1177/2325967119843355
- 380 14. Jackson T, Fabricant PD, Beck N, Storey E, Patel NM, Ganley TJ. Epidemiology, Injury  
381 Patterns, and Treatment of Meniscal Tears in Pediatric Patients: A 16-Year Experience of a  
382 Single Center. *Orthop J Sports Med.* 2019;7(12):2325967119890325.  
383 doi:10.1177/2325967119890325
- 384 15. Vinagre G, Cruz F, Alkhelaifi K, D'Hooghe P. Isolated meniscus injuries in skeletally  
385 immature children and adolescents: state of the art. *J ISAKOS.* 2022;7(1):19-26.  
386 doi:10.1136/jisakos-2020-000496
- 387 16. Räber DA, Friederich NF, Hefti F. Discoid Lateral Meniscus in Children. Long-Term  
388 Follow-up After Total Meniscectomy. *J Bone Joint Surg Am.* 1998;80(11):1579-1586.
- 389 17. Tuca M, Luderowski E, Rodeo S. Meniscal transplant in children. *Curr Opin Pediatr.*  
390 2016;28(1):47-54. doi:10.1097/MOP.0000000000000306
- 391 18. Riboh JC, Tilton AK, Cvetanovich G, Campbell KA, Cole BJ. Outcomes of Meniscal  
392 Allograft Transplantation in the Pediatric Athlete. *Orthop J Sports Med.* 2015;3(7\_suppl2):1-  
393 6. doi:10.1177/2325967115S00128
- 394 19. Getgood A, Laprade RF, Verdonk P, et al. International Meniscus Reconstruction Experts  
395 Forum (IMREF) 2015 Consensus Statement on the Practice of Meniscal Allograft  
396 Transplantation. *Am J Sports Med.* 2017 May;45(5):1195-1205.  
397 doi:10.1177/0363546516660064
- 398 20. Mascarenhas R, Yanke AB, Frank RM, Butty DC, Cole BJ. Meniscal allograft  
399 transplantation: preoperative assessment, surgical considerations, and clinical outcomes. *J*  
400 *Knee Surg.* 2014;27(6):443-458. doi:10.1055/s-0034-1382080
- 401 21. Garcia GH, Christian DR, Redondo ML, Liu JN, Yanke AB, Cole BJ. 3 - Meniscus  
402 Transplantation. In: Thompson SR, Schmitz MR, eds. *Complications in Orthopaedics:*  
403 *Sports Medicine.* Elsevier; 2019:17-27. doi:10.1016/B978-0-323-54598-3.00003-5
- 404 22. Gomoll A, Farr J, Cole BJ. CHAPTER 47 - Allograft Meniscus Transplantation: Bridge in  
405 Slot Technique. In: Gomoll AH, Rihn J, Cole BJ, Sekiya JK, eds. *Surgical Techniques of the*  
406 *Shoulder, Elbow, and Knee in Sports Medicine.* W.B. Saunders; 2008:459-469.  
407 doi:10.1016/B978-1-4160-3447-6.50049-1
- 408 23. Pollard ME, Kang Q, Berg EE. Radiographic sizing for meniscal transplantation.  
409 *Arthroscopy.* 1995;11(6):684-687. doi:10.1016/0749-8063(95)90110-8
- 410 24. Liu JN, Gowd AK, Redondo ML, et al. Establishing Clinically Significant Outcomes After  
411 Meniscal Allograft Transplantation. *Orthop J Sports Med.* 2019;7(1):1-9.  
412 doi:10.1177/2325967118818462

- 413 25. Bin SI, Nha KW, Cheong JY, Shin YS. Midterm and Long-term Results of Medial Versus  
414 Lateral Meniscal Allograft Transplantation: A Meta-analysis. *Am J Sports Med.* 2018  
415 *Apr*;46(5):1243-1250. doi:10.1177/0363546517709777
- 416 26. Novaretti JV, Patel NK, Lian J, et al. Long-Term Survival Analysis and Outcomes of  
417 Meniscal Allograft Transplantation With Minimum 10-Year Follow-Up: A Systematic  
418 Review. *Arthroscopy.* 2019;35(2):659-667. doi:10.1016/j.arthro.2018.08.031
- 419 27. Kimura Y, Yamamoto Y, Sasaki S, et al. Meniscus Allograft Transplantation Obtained From  
420 Adult Patients Undergoing Total Knee Arthroplasty May be Used for Younger Patients After  
421 Lateral Discoid Meniscus Meniscectomy. *Arthrosc Sports Med Rehabil.* 2021;3(6):e1679-  
422 e1685. doi:10.1016/j.asmr.2021.07.024
- 423 28. De Bruycker M, Verdonk PeterCM, Verdonk RC. Meniscal allograft transplantation: a meta-  
424 analysis. *SICOT J.* 2017;3(33):1-15. doi:10.1051/sicotj/2017016
- 425 29. Grassi A, Di Paolo S, Coco V, et al. Survivorship and Reoperation of 324 Consecutive  
426 Isolated or Combined Arthroscopic Meniscal Allograft Transplants Using Soft Tissue  
427 Fixation. *Am J Sports Med.* 2023;51(1):119-128. doi:10.1177/03635465221131522
- 428 30. Medial and Lateral Meniscus Allograft Transplantation Showed No Difference With Respect  
429 to Graft Survivorship and Clinical Outcomes: A Comparative Analysis With a Minimum 2-  
430 Year Follow-Up. *Arthroscopy.* 2020;36(12):3061-3068. doi:10.1016/j.arthro.2020.07.025
- 431 31. Wagner KR, Kaiser JT, Knapik DM, et al. Patient-Specific Variables Associated with Failure  
432 to Achieve Clinically Significant Outcomes After Meniscal Allograft Transplantation at  
433 Minimum 5-Year Follow-Up. *Arthroscopy.* Published online April 26, 2023:S0749-  
434 8063(23)00307-9. doi:10.1016/j.arthro.2023.03.031
- 435 32. Zhang S, Li H, Li H, Hua Y. Bone bridge fixation has superior biomechanics on posterior  
436 knees to bone plug fixation after lateral meniscal allograft transplantation - A biomechanical  
437 study simulating partial weight-bearing conditions. *Knee.* 2021;32:64-71.  
438 doi:10.1016/j.knee.2021.08.007
- 439 33. Ow ZGW, Cheong CK, Hai HH, et al. Securing Transplanted Meniscal Allografts Using  
440 Bone Plugs Results in Lower Risks of Graft Failure and Reoperations: A Meta-analysis. *Am*  
441 *J Sports Med.* 2022;50(14):4008-4018. doi:10.1177/03635465211042014
- 442 34. Ramme AJ, Strauss EJ, Jazrawi L, Gold HT. Cost effectiveness of meniscal allograft for torn  
443 discoid lateral meniscus in young women. *Phys Sportsmed.* 2016;44(3):278-282.  
444 doi:10.1080/00913847.2016.1197762
- 445 35. Liu JN, Agarwalla A, Garcia GH, et al. Return to Sport and Work After High Tibial  
446 Osteotomy With Concomitant Medial Meniscal Allograft Transplant. *Arthroscopy.*  
447 2019;35(11):3090-3096. doi:10.1016/j.arthro.2019.05.053
- 448 36. Chalmers PN, Karas V, Sherman SL, Cole BJ. Return to high-level sport after meniscal  
449 allograft transplantation. *Arthroscopy.* 2013;29(3):539-544. doi:10.1016/j.arthro.2012.10.027

450 37. Rosso F, Bisicchia S, Bonasia DE, Amendola A. Meniscal Allograft Transplantation: A  
451 Systematic Review. *Am J Sports Med.* 2015;43(4):998-1007.  
452 doi:10.1177/0363546514536021

453

#### 454 **Figure Legends**

455 Figure 1: Preoperative and postoperative patient-reported outcomes following primary meniscal  
456 allograft transplantation were collected. Mean scores for Lysholm (Lys), International Knee  
457 Documentation Committee (IKDC) subjective form, and Knee Injury and Osteoarthritis Outcome  
458 Score (KOOS) subscale questionnaires increased at 1-year, 2-year, and most-recent follow-up  
459 timepoints when compared to baseline scores. ADL, activities of daily living; QOL, quality of life;  
460 SXS, symptoms. Error bars represent standard deviation. \* indicates a mean significantly greater  
461 compared to preoperative scores ( $p < 0.05$ ). \*\* indicates a significant increase compared to most-  
462 recent scores ( $p = 0.048$ ).

463

464 Figure 2: Kaplan-Meier survival analysis for (A) meniscal reoperation and (B) graft failure  
465 werestratified by sex. Overall probability of being reoperation-free at 1, 2, 5, and 10 years were  
466 96%, 91%, 80%, 71%, respectively. Survival free from failure at 1, 2, 5, and 10 years were 100%,  
467 100%, 93%, 93%, respectively. Log-rank testing demonstrated no significant difference in survival  
468 distributions between male and female sex for reoperation and failure ( $p = 0.110$  and  $0.710$ ,  
469 respectively).

470



Table 1: Demographics and Intraoperative Variables

| Characteristic                | Post-operative Status        |                              |                             | p-values                   |                               |
|-------------------------------|------------------------------|------------------------------|-----------------------------|----------------------------|-------------------------------|
|                               | None,<br>N = 30 <sup>1</sup> | Reop,<br>N = 11 <sup>1</sup> | Fail,<br>N = 3 <sup>1</sup> | None vs. Reop <sup>2</sup> | None vs. Failure <sup>2</sup> |
| Sex (female)                  | 20 (67%)                     | 11 (100%)                    | 2 (67%)                     | <b>0.039</b>               | >0.999                        |
| Age (years)                   | 16.29 ± 1.11                 | 15.90 ± 1.16                 | 15.53 ± 2.16                | 0.303                      | 0.594                         |
| BMI                           | 24.1 ± 2.9                   | 21.6 ± 4.3                   | 23.4 ± 3.6                  | 0.072                      | 0.810                         |
| Lateral meniscus transplanted | 24 (80%)                     | 8 (73%)                      | 3 (100%)                    | 0.660                      | >0.999                        |
| Concomitant procedure         | 21 (81%)                     | 5 (45%)                      | 1 (33%)                     | 0.051                      | 0.136                         |
| OCA                           | 12 (40%)                     | 1 (9%)                       | 1 (33%)                     | 0.127                      | >0.999                        |
| ACI                           | 5 (17%)                      | 3 (27%)                      | 0 (0%)                      | 0.660                      | >0.999                        |
| HTO                           | 1 (3%)                       | 0 (0%)                       | 0 (0%)                      | >0.999                     | >0.999                        |
| DFO                           | 4 (13%)                      | 0 (0%)                       | 0 (0%)                      | 0.559                      | >0.999                        |
| MFX                           | 3 (10%)                      | 0 (0%)                       | 0 (0%)                      | 0.551                      | >0.999                        |
| ACLR                          | 5 (17%)                      | 1 (9%)                       | 0 (0%)                      | >0.999                     | >0.999                        |

<sup>1</sup>categorical variables listed as n (% of respective cohort); continuous variables listed as mean ± SD

<sup>2</sup>Fisher's exact test; Wilcoxon rank sum test

OCA, osteochondral allograft transplantation; ACI, autologous chondrocyte implantation; HTO, high tibial osteotomy; DFO, distal femoral osteotomy; MFX, microfracture; ACLR, anterior cruciate ligament reconstruction.

Reoperations consist of any surgery related to the transplanted meniscus (arthroscopic evaluation due to meniscal symptoms, debridement, meniscectomy) but excludes revision meniscal allograft transplantation. Failure defined as revision meniscal allograft transplantation or conversion to unicompartmental or total knee arthroplasty.

**Table 2: Patient-Reported Outcomes in Patients Free of Graft Failure at 5-Year Minimum Follow-Up**

| Characteristic | Baseline | 1-Year  | P-value | 2-Year    | P-value | Most-Recent | P-value |
|----------------|----------|---------|---------|-----------|---------|-------------|---------|
| Lysholm        | 49 ± 24  | 77 ± 18 | .005    | 84 ± 19 † | .001    | 74 ± 16     | .018    |
| IKDC           | 38 ± 19  | 57 ± 27 | .042    | 80 ± 19   | <.001   | 71 ± 20     | .005    |
| ADL            | 72 ± 21  | 92 ± 10 | .014    | 95 ± 10   | .001    | 94 ± 8      | .006    |
| Pain           | 59 ± 19  | 84 ± 11 | .016    | 87 ± 10   | <.001   | 85 ± 11     | .001    |
| QOL            | 29 ± 20  | 51 ± 20 | .001    | 65 ± 26   | .007    | 60 ± 24     | .006    |
| Sport          | 31 ± 20  | 69 ± 13 | .003    | 74 ± 15   | .021    | 64 ± 25     | .002    |
| SXS            | 57 ± 16  | 77 ± 14 | .001    | 82 ± 13   | <.001   | 73 ± 17     | .004    |

473 Patient-reported outcome scores at preoperative, 1-year, 2-year, and a minimum 5-year follow-  
 474 up. Questionnaires included are Lysholm, International Knee Documentation Committee (IKDC)  
 475 subjective form, and Knee osteoarthritis and outcome score (KOOS) subscales (ADL, activities  
 476 of daily living; Pain; QOL, quality of life; Sport; SXS, symptoms). Significance determined by  
 477 Wilcoxon Signed-Rank testing. Continuous variables listed as mean ± SD.

478 † - significantly greater ( $p = .048$ ), compared to most-recent follow-up

479

| <b>Table 3: Clinically Significant Outcomes at Five-Year Minimum</b> |                           |
|--|---------------------------|
| <b>Characteristic</b>  | <b>N = 41<sup>1</sup></b> |
| <b>MCID</b>  |                           |
| IKDC   | 10 / 16 (62%)             |
| Lysholm  | 8 / 13 (62%)              |
| Pain   | 11 / 17 (65%)             |
| Symptoms   | 11 / 19 (58%)             |
| Sport  | 12 / 14 (86%)             |
| ADL  | 9 / 17 (53%)              |
| QOL  | 10 / 17 (59%)             |

| <b>Characteristic</b>  | <b>N = 41<sup>1</sup></b> |
|--|---------------------------|
| <b>PASS</b>  |                           |
| IKDC   | 25 / 33 (76%)             |
| Lysholm  | 23 / 29 (79%)             |
| Pain   | 26 / 32 (81%)             |
| Symptoms   | 26 / 32 (81%)             |
| Sport  | 24 / 32 (75%)             |
| ADL  | 24 / 31 (77%)             |
| QOL  | 25 / 31 (81%)             |
| <b>SCB</b>   |                           |
| IKDC   | 5 / 16 (31%)              |
| Lysholm  | 3 / 13 (23%)              |
| Pain   | 7 / 17 (41%)              |
| Symptoms   | 9 / 19 (47%)              |
| Sport  | 7 / 14 (50%)              |
| ADL  | 6 / 17 (35%)              |
| QOL  | 10 / 17 (59%)             |
| <sup>1</sup> Patients were included if they did not fail prior to five-year follow-up.   |                           |
| ADL, activities of daily living; IKDC, International Knee Documentation Committee subjective form; KOOS, Knee Injury and Osteoarthritis Outcome Score; MCID, minimal clinically important difference; PASS, patient acceptable symptomatic state; QOL, quality of life; SCB, substantial clinical benefit. |                           |

480

481

|                 | <b>Threshold</b> | <b>SN</b> | <b>SP</b> | <b>AUC</b> |
|-----------------|------------------|-----------|-----------|------------|
| <b>MCID</b>     |                  |           |           |            |
| <b>IKDC</b>     | 11.5             |           |           |            |
| <b>Lysholm</b>  | 11.9             |           |           |            |
| <b>KOOS</b>     |                  |           |           |            |
| <b>Pain</b>     | 12.0             |           |           |            |
| <b>Symptoms</b> | 11.1             |           |           |            |
| <b>Sport</b>    | 13.2             |           |           |            |
| <b>QOL</b>      | 18.4             |           |           |            |
| <b>ADL</b>      | 13.9             |           |           |            |
| <b>PASS</b>     |                  |           |           |            |

|                 |      |       |       |              |
|-----------------|------|-------|-------|--------------|
| <b>IKDC</b>     | 54.2 | 95.0  | 100.0 | 0.995        |
| <b>Lysholm</b>  | 61.0 | 89.4  | 100.0 | 0.964        |
| <b>KOOS</b>     |      |       |       |              |
| <b>Pain</b>     | 72.2 | 100.0 | 100.0 | 0.999        |
| <b>Symptoms</b> | 57.1 | 89.4  | 75.0  | 0.822        |
| <b>Sport</b>    | 42.5 | 94.7  | 100.0 | 0.999        |
| <b>QOL</b>      | 46.8 | 94.7  | 100.0 | 0.986        |
| <b>ADL</b>      | 88.1 | 89.5  | 100.0 | 0.973        |
| <b>SCB</b>      |      |       |       |              |
| <b>IKDC</b>     | 30.6 | 60.0  | 85.7  | <b>0.686</b> |
| <b>Lysholm</b>  | 24.5 | 75.0  | 71.4  | 0.750        |
| <b>KOOS</b>     |      |       |       |              |
| <b>Pain</b>     | 16.5 | 83.3  | 50.0  | <b>0.583</b> |
| <b>Symptoms</b> | 17.6 | 66.7  | 62.5  | <b>0.562</b> |
| <b>Sport</b>    | 40.0 | 40.0  | 100.0 | <b>0.667</b> |
| <b>QOL</b>      | 9.4  | 50.0  | 71.4  | <b>0.464</b> |
| <b>ADL</b>      | 22.5 | 40.0  | 87.5  | <b>0.575</b> |

Legend: Thresholds for minimal clinically important difference (MCID), patient acceptable symptomatic state (PASS), and substantial clinic benefit (SCB) were calculated using both revision and primary meniscal allograft transplantation cohorts. Patient reported outcome measures analyzed included Lysholm, subjective International Knee Documentation Committee (IKDC), and Knee Injury and Osteoarthritis Outcome Score (KOOS) subscales. ADL, activities of daily living; AUC, area under the curve; QOL, quality of life; SN, sensitivity; SP, specificity.

482

| <b>Supplemental Table 2: Reoperation and Failure Data Stratified by Meniscal Laterality</b> |                            |                           |                     |
|---|----------------------------|---------------------------|---------------------|
| <b>Variable</b>   | <b>Lateral<sup>1</sup></b> | <b>Medial<sup>1</sup></b> | <b>p-value</b>      |
| <b>Meniscal reoperation type</b>  |                            |                           | >0.999 <sup>2</sup> |
| None  | 24 (69%)                   | 6 (67%)                   |                     |
| Partial meniscectomy  | 7 (20%)                    | 2 (22%)                   |                     |
| Total Meniscectomy  | 3 (9%)                     | 1 (11%)                   |                     |
| Repair  | 1 (3%)                     | 0 (0%)                    |                     |
| <b>Time to reoperation</b>  | 4.3 ± 4.1                  | 8.0 ± 4.6                 | 0.291 <sup>3</sup>  |

| <b>Supplemental Table 2: Reoperation and Failure Data Stratified by Meniscal Laterality</b>   |                            |                           |                     |
|---|----------------------------|---------------------------|---------------------|
| <b>Variable</b>   | <b>Lateral<sup>1</sup></b> | <b>Medial<sup>1</sup></b> | <b>p-value</b>      |
| <b>Failure</b>  | 3 (9%)                     | 0 (0%)                    | >0.999 <sup>2</sup> |
| <sup>1</sup> categorical variables listed as n (% of respective medial or lateral meniscal allograft transplantation group); continuous variables listed as mean ± standard deviation.<br><sup>2</sup> Fisher's exact test<br><sup>3</sup> Wilcoxon rank-sum test |                            |                           |                     |

Journal Pre-proof

## Preoperative and Postoperative Patient Reported Outcomes





